Abstract
Advances in the technetium chemistry have significantly enhanced the development of Tc-99m radiopharmaceuticals for clinical use. Efforts in designing novel Tc-99m labeled receptor or site-specific imaging agents using [Tc(v)O](+3)N(2)S(2) core have produced useful imaging agents for single photo emission computed tomography (SPECT). The success in developing Tc-99m TRODAT-1 for CNS dopamine transporters (DAT) serves as the first example of Tc-99m site-specific imaging of human brain. New innovative Tc-99m labeled site-specific agents are particularly suitable to develop simple and useful routine diagnostic procedures.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Brain Chemistry*
-
Dopamine Plasma Membrane Transport Proteins
-
Humans
-
Membrane Glycoproteins*
-
Membrane Transport Proteins / analysis*
-
Nerve Tissue Proteins*
-
Organotechnetium Compounds / metabolism
-
Radiopharmaceuticals*
-
Technetium*
-
Tomography, Emission-Computed
-
Tomography, Emission-Computed, Single-Photon
-
Tropanes / metabolism*
Substances
-
Dopamine Plasma Membrane Transport Proteins
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
Organotechnetium Compounds
-
Radiopharmaceuticals
-
SLC6A3 protein, human
-
Tropanes
-
technetium Tc 99m TRODAT-1
-
Technetium